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rodeoxyglucose positron emission tomography (FDG-PET).
Even a test without any discriminatory value (which would
classify all patients as having a CMR) would have an
excellent NPVof 96.6% (85 of 88) in that scenario. Thus, the
FDG-PET results have only minor additional value. Of note,
in diffuse large B-cell lymphoma, which is known to have a
worse prognosis than PMBCL, the NPVof end-of-treatment
FDG-PET diminishes drastically (3). One study even showed
that patients with high-risk diffuse large B-cell lymphoma
have a very dismal progression-free survival of only 38.5%
despite attaining a CMR (4, 5). The failure of FDG-PET to
exclude residual disease results from its low spatial resolu-
tion (6). Also, the positive predictive value in the study by
Ceriani et al (1) was only 30% (3 of 10) when the Lugano
criteria were applied. Because biopsy confirmation before
salvage therapy was not reported, even these 3 cases of re-
sidual disease might be questionable. In addition, post-
therapy FDG-PET scans have a high (biopsy-proven) false-
positive rate (7), and death can result from erroneously
initiated toxic high-dose therapies rather than persistent
lymphoma. However, despite early (presumed) identification
of refractory disease, 3 of 3 patients died, which confirms the
results of previous studies that early (asymptomatic) residual
disease detection does not improve outcomes (8).
In conclusion, the NPV of post-therapy FDG-PET is
highly influenced by the low incidence of disease relapse in
PMBCL. Furthermore, early detection of residual disease in
PMBCL using the Lugano criteria is not feasible, consid-
ering the low positive predictive value of FDG-PET in this
setting and that early residual disease detection does not
improve patient outcomes.
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study. J Clin Oncol 2015;33:3993-3998.In Reply to Adams and KweeTo the Editor: Biologic and clinical particularities to pri-
mary mediastinal B-cell lymphoma (PMBCL) exist that
confound the assertions in the letter from Adams and
Kwee (1, 2). They did not consider that nearly all patients
will have a bulky mediastinal mass at diagnosis and
similarly will have significant residual lesions visible on
computed tomography scans after therapy, whether suc-
cessful or not. Moreover, despite the excellent outcomes
for most patients, the few who develop recurrent disease
are extremely difficult to salvage with second-line therapy,
making optimization of first-line therapy the dominant
priority.
Although the high success rate of therapy results in a high
negative predictive value for fluoro-deoxyglucose positron
emission tomography (FDG-PET), it remains the best
discriminator of the outcome and is certainly greatly supe-
rior to computed tomography alone. The suggestion that
FDG-PET scanning cannot wholly exclude the presence of
residual disease owing to its low resolution, although theo-
retically possible, has simply not been borne out by our data
for PMBCL, which showed that the FDG-PET findings are a
valid surrogate of long-term outcomes (1, 3, 4).
The essential clinical need is to know whether the
post-treatment complete metabolic response predicts
long-term remission. In this context, PET-computed to-
mography will be superior to other imaging methods.
Also, in PMBCL, owing to the intrinsic characteristics of
the disease and the efficacy of available therapies, FDG-
PET will perform much better than in other diffuse large
B-cell lymphomas.
The assertion that early identification of relapse has no
effect on outcome is also flawed, because it was determined
Volume 97  Number 4  2017 Comments 871from data from patients with other types of diffuse large
B-cell lymphoma in complete remission. We would support
the need for repeat biopsy wherever possible to confirm the
true PET-positive findings. However, mediastinal biopsy of
small residual lesions can be technically difficult, and it is
often necessary to begin treatment of overt clinical and
radiologic progression without delay.
Of the 3 patients who died in our series, progressive
disease was confirmed by clinical and imaging follow-up
studies, and all the deaths were related to the lymphoma.
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